Tecentriq

Exelixis
Biotech

Exelixis’ Cabometyx successor misses primary endpoint in CRC trial

While the zanzalintinib study is still technically positive, it could draw FDA scrutiny because Exelixis changed its primary endpoint twice.
Angus Liu Jun 22, 2026 3:40pm
pancreatic cancer pancreas model

Novocure touts positive data in metastatic pancreatic cancer

Mar 27, 2026 10:32am
Tecentriq
Favicon Fierce Pharma

Roche touts Tecentriq biomarker win in bladder cancer

Aug 18, 2025 4:17pm
Gates entrance

Roche puts 'stronger gates' on ph. 3 pipeline to limit failures

Sep 11, 2023 11:15am
Roche

Roche posts TIGIT survival data after 'inadvertent disclosure'

Aug 23, 2023 5:36am
An artists impression of cancer cells The cancer cells are lavender on a yellow-gold background

PD-1 R&D tapers off as new molecules capture interest: IQVIA

May 24, 2023 2:09pm